Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTECT-Lynch: DC Vaccination for Tumour Prevention in Lynch Syndrome Carriers
NCT07609901Phase 3Not yet recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2026
- Primary completion
- Oct 2032
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Lynch syndrome (LS) (2 arms), sponsored by Radboud University Medical Center. Primary endpoint: Disease-free survival at 58.5 months. Planned start Oct 2026; status: not yet recruiting.
02
Conditions
Lynch syndrome (LS)
Beyond the preview
Go deeper on NCT07609901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07609901.